Results of final overall survival analysis from the global, randomized phase 3 MATTERHORN clinical trial show that adding perioperative durvalumab…
gastric cancer
The HERIZON-GEA-01 open-label, phase 3 clinical trial was designed to compare first-line treatment with the bispecific antibody zanidatamab plus chemotherapy…
Results from the MATTERHORN phase 3 study demonstrate that immunotherapy in combination with standard chemotherapy before and after surgery significantly…
As part of the Severo Ochoa Patient and Citizen Involvement Programme, the 4th Patient Day was held on 10 April,…
According to a recent report (1) gastric cancer (GC) is responsible for over one million new cases worldwide in 2020, with an…
